Novo Nordisk A/S logo

Novo Nordisk A/S

NOVO-B.CO
HealthcareCPHDenmark
235.85DKK+0.55 (+0.23%)

About Novo Nordisk

Novo Nordisk A/S is a healthcare company engaged in the development, manufacture, and marketing of pharmaceutical products globally.

It operates through two segments:

  • Diabetes and Obesity Care: This segment delivers a comprehensive range of products, including insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity treatments, and therapies for other chronic diseases.

  • Biopharmaceuticals: Focuses on products for haemophilia, growth disorders, and hormone replacement therapy.

Novo Nordisk maintains collaborative agreements to enhance research and product development. Notably, it has partnerships with Gilead Sciences, Inc., and Lumen Bioscience, Inc., the latter focusing on strategies for delivering oral biologics to treat cardiometabolic diseases.

Founded in 1923, the company is headquartered in Bagsvaerd, Denmark.

Novo Nordisk's Business Strategy

Novo Nordisk focuses on developing and commercializing innovative therapies for chronic diseases, with a particular emphasis on diabetes, obesity and metabolic disorders. The company has built a global leadership position in glucagon-like peptide-1 (GLP-1) based medicines, which regulate blood sugar and appetite. Flagship products include…

Available on Finplify

Free account required

Sign up free

Our Take on Novo Nordisk

Pros:

Diabetes & Obesity Care Leader: Novo Nordisk is the world’s largest insulin manufacturer and a dominant player in the fast-growing GLP-1 drug class, which treats both diabetes and obesity. Its therapies have shown strong clinical results and high patient demand globally.

✅ **Obesity Treatments…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
CPH
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
CEO
Maziar Mike Doustdar
Employees
77,406
IPO Date
2001-01-06
ISIN
DK0062498333
Website
novonordisk.com

Key Metrics

Market Cap
1.05TDKK
P/E Ratio (TTM)
10.21
Net Profit Margin
33.14%
Debt / Asset Ratio
0.24
Dividend Yield (TTM)
4.95%
Volume
2.14M
Avg Volume
8.01M
Shares Outstanding
4.44B
Free Float
71.76%
β Beta
0.40
52W Range
224.3 - 533.4

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
5.0/5Excellent
Liquidity
2.0/5Weak
Leverage
4.0/5Good
Cash Flow
4.0/5Good
Valuation
3.9/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on Novo Nordisk

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.